The preliminary outcome of the combination of immunotherapy and targeted therapy after recurrence and metastasis for hereditary leiomyomatosis and renal cell cancer-a case report.
Hereditary leiomyomatosis and renal cell cancer (HLRCC)-associated kidney cancer is a rare and exceptionally aggressive, with early metastasis and die at a young age. Most reported patients usually present with back pain and hematuria, and died within 5 years after diagnosis. Currently, there is not a guideline or census about the management of HLRCC. On April 19, 2019, the Food and Drug Administration (FDA) of the USA approved the combination of pembrolizumab and axitinib for first-line treatment of patients with advanced renal cell carcinoma based on the results of KEYNOTE-426 trial. Thus, the combination of immunotherapy and targeted therapy should be considered for HLRCC. We present a case of 46-year-old man without family history, possessing specific mutation and sensitive to the combination of immunotherapy and targeted therapy. After he completed seven cycles of combined treatments, his discomfort improved and the lesions of pleura almost disappeared and the mass in the left kidney area was basically stable. This patient might be the first one to receive the combination therapy and the efficacy seemed acceptable.
2020 Translational Andrology and Urology. All rights reserved.
基金：
The study was supported by the 1.3.5 project for disiplines of excellence, West China Hospital, Sichuan University (ZY2016104) and Pillar Program from Department of Science and Technology of Sichuan Province (2018SZ0219).
语种：
外文
PubmedID：
中科院(CAS)分区：
出版当年[2020]版：
大类|3 区医学
小类|3 区男科学3 区泌尿学与肾脏学
最新[2023]版：
大类|3 区医学
小类|4 区男科学4 区泌尿学与肾脏学
第一作者：
第一作者机构：[1]Department of Urology, Institute of Urology, West China Hospital, Sichuan University, Chengdu 610041, China
共同第一作者：
通讯作者：
通讯机构：[1]Department of Urology, Institute of Urology, West China Hospital, Sichuan University, Chengdu 610041, China[*1]Department of Urology, Institute of Urology, West China Hospital, Sichuan University, Guoxue Xiang #37, Chengdu 610041, China
推荐引用方式(GB/T 7714)：
Feng Dechao,Yang Yubo,Han Ping,et al.The preliminary outcome of the combination of immunotherapy and targeted therapy after recurrence and metastasis for hereditary leiomyomatosis and renal cell cancer-a case report.[J].Translational andrology and urology.2020,9(2):789-793.doi:10.21037/tau.2019.12.37.
APA：
Feng Dechao,Yang Yubo,Han Ping&Wei Xin.(2020).The preliminary outcome of the combination of immunotherapy and targeted therapy after recurrence and metastasis for hereditary leiomyomatosis and renal cell cancer-a case report..Translational andrology and urology,9,(2)
MLA：
Feng Dechao,et al."The preliminary outcome of the combination of immunotherapy and targeted therapy after recurrence and metastasis for hereditary leiomyomatosis and renal cell cancer-a case report.".Translational andrology and urology 9..2(2020):789-793
